Palvella Reports Q3 2026 Financial Results and FDA Priority Review for QTORIN
Palvella (PVLA) reported its third-quarter 2026 financial results, highlighted by a significant regulatory milestone: the FDA has accepted the New Drug Application for QTORIN rapamycin to treat microcystic lymphatic malformations. The FDA granted priority review with a target action date set for February 28, 2027. Management anticipates peak annual U.S. sales for this candidate could exceed $1 billion, supported by an estimated patient population of over 30,000 and projected annual therapy costs between $100,000 and $200,000. Financially, the company reported a net loss of $24.6 million ($1.70 per share) for the quarter, an increase from $11.3 million in the prior year, driven by rising R&D and G&A expenses. Despite the widening loss, Palvella maintains a strong liquidity position with $236.7 million in cash and equivalents. Looking ahead, the company plans to initiate Phase 3 studies for cutaneous venous malformations and Phase 2 trials for QTORIN-pitavastatin in the fourth quarter of 2026.
Tickers: $PVLA
Topics: Drug Development FDA Approval Process Financial Results Microcystic Lymphatic Malformations
Read the full article at Motley Fool
Part of the story Palvella Reports Q3 2026 Financial Results and FDA Priority Review for QTORIN (5 articles)